|Assessment Status||Rapid Review Complete|
|Drug||Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF)|
|Indication||For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.|
|Rapid review commissioned||28/06/2016|
|Rapid review completed||11/07/2016|
|Rapid review outcome||Reimbursement Not Recommended|
4th October 2016 – The NCPE has recommended reimbursement following a re-submission of updated clinical evidence.